Business Wire

Business Figures for the First Half of 2017: Sartorius Continues to Grow

Del

Sartorius (FWB:SRT), a leading international laboratory and pharmaceutical equipment supplier, continues on the growth track. In the first half of 2017, solid organic business development and two acquisitions led to a significant increase in sales revenue and earnings1.

"Sartorius has continued its dynamic, profitable development," said CEO and Executive Board Chairman Dr. Joachim Kreuzburg in commenting on the company's first-half performance. "Both divisions achieved solid organic growth in an environment that was especially challenging in North America, and have made quick progress in integrating the businesses most recently acquired. In the Lab Products & Services Division, the bioanalytics unit newly created by our acquisitions has already contributed significant revenues and earnings. We see further considerable growth potential ahead for this business just as for the field of bioprocess data analytics, which our Bioprocess Solutions Division recently entered through an acquisition. For the second half, we expect a somewhat improved market environment in North America and confirm our sales and earnings forecast for both divisions and the Group."

Business development of the Sartorius Group

In the first half of 2017, sales revenue rose by 11.5% in constant currencies (reported: 12.6%) from 625.4 million euros to 704.1 million euros. The Asia/Pacific region recorded the highest gain, with sales up 34.8% to 172.2 million euros. In the EMEA2 and Americas regions, Sartorius sales grew by 5.9% to 302.9 million euros and by 4.8% to 229.0 million euros, respectively, against a high prior-year revenue base (all regional growth figures in constant currencies).

Earnings in the reporting period increased overproportionately again relative to sales. Underlying EBITDA thus rose 13.8%, primarily due to economies of scale, from 153.4 million euros to 174.5 million euros. The respective margin reached 24.8% relative to 24.5% a year ago. Relevant net profit3 for the Group increased 13.6% from 62.4 million euros to 70.9 million euros. This corresponds to earnings per ordinary share of 1.03 euros (H1 2016: 0.91 euros) and per preference share, 1.04 euros (H1 2016: 0.92 euros).

The company's key financial indicators remained at robust levels even after the most recent acquisitions of Essen BioScience in March 2017 and Umetrics in April 2017. At the end of the reporting period, the company's equity ratio was 32.6% and its ratio of net debt to underlying EBITDA stood at 2.7 (Dec. 31, 2016: 42.0%% and 1.5, resp.). At 12.9%, the capex ratio in the first half was within the range expected. Investment activities focused on expansion of the plant for manufacturing single-use bags and filters in Yauco, Puerto Rico, as well as on the combination and expansion of Group headquarters in Goettingen, Germany.

As of the reporting date on June 30, 2017, Sartorius employed 7,364 people total, 453 more than as of December 31, 2016 (around +7%).

Business development of the divisions

As expected, market growth for the bioprocess business normalized after 2015 and 2016, two years of extraordinarily strong expansion. Sales revenue of the Bioprocess Solutions Division, which focuses on single-use products for the manufacture of biopharmaceuticals, rose despite the high comparable base of the previous year, by 8.0% in constant currencies to 510.9 million euros (reported: +8.8%). In particular, development in the Americas was influenced by relatively soft customer demand and limited delivery capacity for cell culture media, while business in Asia grew very dynamically, especially due to relatively large equipment projects. Consolidation of kSep acquired in July 2016 and Umetrics purchased in April 2017 contributed close to one percentage point to growth. Underlying EBITDA for Bioprocess Solutions rose overproportionately with respect to sales, by 10.0% to 140.8 million euros. The division's corresponding margin was 27.6% relative to 27.3% in the prior-year period.

The Lab Products & Services Division, which offers laboratory instruments and technologies primarily for the pharma sector and public research, expanded very dynamically in the first six months. This was also due to its acquisition of cell analysis specialist Essen BioScience. Its sales thus rose 22.1% (reported: +24.1%) to 193.2 million euros. While organic growth was about 7%, acquisitions contributed around 15% to the division's revenue growth. Reporting a gain of 33.1%, Lab Products & Services significantly increased its underlying EBITDA overproportionately from 25.3 million euros to 33.7 million euros. Its corresponding margin was 17.5% relative to 16.3% in the previous period.

Forecast for the full year confirmed

Based on the company's first-half business performance, management confirms its forecast raised at the beginning of April for the full year. Management thus projects that Group sales revenue for the full year will grow by about 12% to 16% and the underlying EBITDA margin will increase slightly more than by half a percentage point over the prior-year figure of 25.0%. The capex ratio for the current fiscal year is projected to remain at around 12% to 15%.

Regarding the two divisions, management continues to anticipate that sales for Bioprocess Solutions will grow by about 9% to 13%, which includes a good one percentage point of non-organic growth to be contributed by the acquired companies kSep and Umetrics. With regard to delivery capacities for cell culture media, management assumes that this situation will normalize during the third quarter of the current year. The division's underlying EBITDA margin is projected to rise by about half a percentage point over the prior-year figure of 28.0%.

For the Lab Products & Services Division, Group management continues to project that, assuming an overall stable economic environment, sales will increase by about 20% to 24%. This includes non-organic growth of around 17 percentage points to be contributed by the companies acquired, IntelliCyt, ViroCyt and Essen BioScience. The division's underlying EBITDA margin is expected to rise by nearly two percentage points compared with the prior-year figure of 16.0%.

All forecasts are based on constant currencies.

1 Sartorius uses underlying EBITDA (earnings before interest, taxes, depreciation and amortization and adjusted for extraordinary items) as the key profitability indicator

2 EMEA = Europe | Middle East | Africa

3 After non-controlling interest, adjusted for extraordinary items and non-cash amortization, as well as based on the normalized financial result and corresponding tax effects

This press release contains statements about the future development of the Sartorius Group. The content of these statements cannot be guaranteed as they are based on assumptions and estimates that harbor certain risks and uncertainties. This is a translation of the original German-language press release. Sartorius shall not assume any liability for the correctness of this translation. The original German press release is the legally binding version. Furthermore, Sartorius reserves the right not to be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.

Current image files

Dr. Joachim Kreuzburg, CEO and Executive Board Chairman of Sartorius AG

www.sartorius.com/fileadmin/media/global/company/Sartorius_Kreuzburg.jpg

Sartorius products used in the manufacture of medications

www.sartorius.com/mediafile/corp/Sartorius_0232_PG9_01_RGB.jpg

Sartorius products used in pharmaceutical research

www.sartorius.com/mediafile/corp/Sartorius_0424_PG14.jpg

Conference call

Dr. Joachim Kreuzburg, CEO and Executive Board Chairman of Sartorius, will discuss the company's results with analysts and investors on Friday, July 21, 2017, at 3:30 p.m. Central European Time (CET) in a teleconference. You may register by clicking on the following link:

http://services.choruscall.de/DiamondPassRegistration/register?confirmationNumber=8963117&linkSecurityString=256e3090d

Alternatively, you can dial into the teleconference, without registering, at:

+49 (0) 69 566 03 6000

His presentation will be available on July 21, 2017, starting at 3:15 p.m. CET, for viewing on our website at:

http://www.sartorius.com/com/group/investor-relations/sartorius-ag/

Upcoming financial dates

October 24, 2017 Publication of nine-month figures (January to September 2017)

A Profile of Sartorius

The Sartorius Group is a leading international pharmaceutical and laboratory equipment provider with two divisions: Bioprocess Solutions and Lab Products & Services. Bioprocess Solutions with its broad product portfolio focusing on single-use solutions helps customers produce biotech medications and vaccines safely and efficiently. Lab Products & Services, with its premium laboratory instruments, consumables and services, concentrates on serving the needs of laboratories performing research and quality assurance at pharma and biopharma companies and on those of academic research institutes. Founded in 1870, the company earned sales revenue of more than 1.3 billion euros in 2016. More than 6,900 people work at the Group's 50 manufacturing and sales sites, serving customers around the globe.

Key Figures for the First Half of 2017

  Sartorius Group   Bioprocess Solutions   Lab Products & Services
in millions of € (unless otherwise specified)   H1
2017
  H1
2016
 

Δ in
%
Reported

 

Δ in
% cc1

  H1
2017
  H1
2016
 

Δ in
%
Reported

 

Δ in
% cc1

  H1
2017
  H1
2016
 

Δ in
%
Reported

 

Δ in
% cc1

Sales Revenue and Order Intake
Sales revenue   704.1   625.4   12.6   11.5   510.9   469.8   8.8   8.0   193.2   155.7   24.1   22.1
- EMEA2   302.9   288.1   5.1   5.9   209.4   207.2   1.0   2.2   93.5   80.8   15.7   15.1
- Americas2   229.0   212.3   7.9   4.8   181.3   181.1   0.1   -2.6   47.7   31.2   53.0   47.5
- Asia | Pacific2   172.2   125.1   37.7   34.8   120.3   81.5   47.6   44.4   52.0   43.6   19.2   17.2
Order intake   741.9   677.6   9.5   8.4   546.9   519.2   5.3   4.4   195.0   158.4   23.1   21.1
Earnings
EBITDA3   174.5   153.4   13.8       140.8   128.1   10.0       33.7   25.3   33.1    
EBITDA margin3 in %   24.8   24.5           27.6   27.3           17.5   16.3        
Net profit for the period4   70.9   62.4   13.6                                    
Financial Data per Share
Earnings per ordinary share4 in €   1.03   0.91   13.7                                    
Earnings per preference share4 in €   1.04   0.92   13.6                                    

1 In constant currencies abbreviated as "cc"

2 Acc. to the customer's location
3 Underlying
4 After non-controlling interest, adjusted for extraordinary items and non-cash amortization, as well as based on the normalized financial result and corresponding tax effects.

Contact information

Sartorius
Petra Kirchhoff
Vice President of Corporate Communications and IR
+49 (0)551.308.1686
petra.kirchhoff@sartorius.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Wealth Dynamix (WDX) Ranks No.18 in the 2017 Tech Track 100 by the Sunday Times and 19th Fastest Growing Technology Company in the UK in the 2017 Deloitte Technology Fast 5023.11.2017 08:00Pressemelding

WDX ranks No.18 in the 17th annual Sunday Times Hiscox Tech Track 100 league table league which consisted of the top 100 private technology, media and telecoms (TMT) companies in Britain. WDX recorded a 155% average annual sales growth per year over the last 3 years with sales reaching £6.4M in September 2016 and £9m by end of September 2017. More recently, in November 2017, WDX also announces ranking No.19 in the 2017 Deloitte UK Technology Fast 50, a ranking of the 50 fastest growing technology companies in the UK. Rankings are based on percentage revenue growth over the last four years of which, WDX grew 1,563% during this period. WDX attributed this revenue growth to the team’s hard work and the positive change in attitude toward technology in the Wealth and Investment Management industry. WDX’s CEO, Gary Linieres credits the team with the company’s revenue growth. He sa

Mobidiag Signs Agreement with Interlux for the Distribution of Amplidiag® Diagnostic Tests and Instruments in Estonia23.11.2017 07:00Pressemelding

Mobidiag Ltd, a Finnish molecular diagnostics company, today announced a distribution agreement with Interlux OÜ, supplier of technologies for medicine, science and biotechnology industry. Under this agreement, Interlux becomes the exclusive distributor of the Amplidiag® product line in Estonia, in vitro diagnostic tests and compatible instrument for the detection of gastrointestinal infections. “Thanks to a large distribution network, our Amplidiag product line is now accessible in most Western European countries. This new distribution agreement allows us to introduce the Amplidiag product line to the Baltic region starting with Estonia. We are then very happy to start this new partnership with Interlux to support us in this new market”, said Miquel Vernet, CCO at Mobidiag. “Cooperation with Mobidiag offers the customers of Interlux high-quality diagnostic results. I believ

OCP Announces Date of 2017 Third Quarter and Nine Month Results22.11.2017 16:59Pressemelding

OCP S.A., a global leader in the fertilizer industry, will release its third quarter and nine month 2017 results on Thursday, November 30, 2017. The results will be available to holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers on the OCP Intralinks portal at 9 a.m. EDT and 2 p.m. Morocco/London time. OCP senior management will host a conference call to discuss 2017 third quarter/nine month results at 10 a.m. EDT and 3 p.m. Morocco/London time on Thursday, November 30, 2017 for holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers. Eligible parties that have not already registered for access to the Intralinks portal may do so by contacting the Investor Relations Department by emailing g.laraki@ocpgroup.ma. About OCP OCP is a global leader in the fert

Tata Motors Charts Out 'Connecting Aspirations' As Its New Corporate Brand Identity in Global Markets22.11.2017 14:46Pressemelding

As part of the company’s transformation journey undertaken in 2016, Tata Motors commenced a comprehensive project to articulate its corporate branding. Basis a thorough analysis of the existing and the desired future state of the Company, Tata Motors has defined its new brand identity as ‘Connecting Aspirations’ across 46 markets, internationally. ‘Connecting Aspirations’, as the new defining maxim, represents the personality of the brand as an interconnected system of mobility solutions, that are intelligent, perceptive, warm and expressive. It’s a symbolic tagline that represents the company’s past, present and future. It is humble yet bold, a statement as well as a challenge. It will define the way Tata Motors communicates with its internal as well as external stakeholders, and work as an all-encompassing guiding principle across business units.” Speaking on the

NelsonHall Positions L&T Technology Services in the Leaders Category for IoT Services22.11.2017 13:50Pressemelding

L&T Technology Services Limited (NSE: LTTS), a leading global pure-play engineering services company announced that it has been positioned in the Leaders Category by independent global research firm, NelsonHall in its latest NEAT evaluation for Internet of Things (IoT) services providers. LTTS is the only global pure-play engineering services to be positioned in the leader’s category. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171122005331/en/ L&T Technology Services Capabilities across IoT Services. (Graphic: Business Wire) LTTS has been identified as a leader relative to its peers’ due to its ability to meet future client requirements as well as deliver immediate benefits to IoT Services clients. Dominique Raviart, IT Services Practice Director, NelsonHall said, “L&T Technol

Smithers Viscient Europe Appoints Alasdair Clipston Director of Chemistry.22.11.2017 10:30Pressemelding

Smithers Viscient, a global contract research organisation (CRO), announced the appointment of Alasdair Clipston to the role of Director of Chemistry. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171122005035/en/ Smithers Viscient Europe Appoints Alasdair Clipston Director of Chemistry. (Photo: Business Wire) Clipston joins Smithers with 15 years spent within contract research and testing organisations including AstraZeneca and Charles River. “Alasdair brings great knowledge and experience to our operational leadership team, particularly in residue and physical chemistry including five batch analysis.” said Steve Dean, Managing Director, Smithers Viscient Europe. Dean continues, “His skills and passion for science coupled with excellent client relationships and strong business unde

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom